



Cytorex Biosciences Completes Cytotoxicity Testing With Its Anti-cancer Compound Cytoreg

For Immediate Release

WESTON, Fla./EWorldWire/July 7, 2004 --- Cytorex Biosciences Inc. reports it has concluded cytotoxicity testing in cancer and healthy cell cultures with its proprietary compound Cytoreg(R), with selective cytotoxicity activity against cancer cells, high anti-oxidant and free radical stress capability. In healthy cells tested at the same doses as cancer cells the cytotoxicity profile is very low, making Cytoreg(R) a potential safe and effective first line agent for the treatment of different cancer indications.

Testing performed by CeeTox Inc. in rat hepatoma (liver cancer) cells, normal hepatocytes (liver), and normal kidney cells indicate a distinctive cytotoxic activity of Cytoreg(R) in cancer cells. "Normally I do not impress easily, but occasionally a project has something truly large to offer, and I think Cytorex could be one of these. In CeeTox, we are very impressed with the exciting Cytoreg(R) data, for which we appreciate the opportunity to be part of its success," indicated James M. McKim, Ph.D., President and CEO of CeeTox Inc. of Kalamazoo, Mich.

"Results show a substantial difference in the levels of inhibition of cancer cell growth, as well as of toxicity, which reinforces the therapeutic potential of Cytoreg(R). Cancer cells present a non-coherent membrane regarding the receptors which make them easily identifiable by Cytoreg(R), as if they were naked or without their regular 'shirts,' and Cytoreg(R) can detect them easily to induce their death, cutting the proliferation and migration of the same. Really, we are in front of a great innovation in the fight against cancer," said Dr. James Kumi-Diaka, PhD, Biology Professor and Cancer Research Scientist of Florida Atlantic University in Davie, Fla.

Cytorex's preclinical data was evaluated by the National Cancer Institute (NCI-Frederick) last year, and has allowed Cytorex to reach a collaboration agreement with the NCI through an extensive research and development program with Cytoreg(R) as potential treatment for glioblastoma multiforme (brain cancer).

The Cytoreg(R) innovative and breakthrough technology allows the pharmacological use of compositions that combine organic acids and inorganic acids (hydrofluoric and sulfuric, among others) to treat disease.

About Cytorex Biosciences Inc.:

Cytorex Biosciences Inc is a privately owned Biotech company from Weston involved in the development of Cytoreg(R) and CytoregUNO(R)(TM), the company's novel therapeutic agents against cancer currently in pre-clinical phase. The company is in the initial stage of a private offering. This is not to be construed as a solicitation to offer or sell securities.

HTML: <http://www.eworldwire.com/pressreleases/10424>

MOBILE: <http://e4mobile.com/pressreleases/10424>

PDF: <http://www.eworldwire.com/pdf/10424.pdf>

ONLINE NEWSROOM: <http://www.eworldwire.com/newsroom/2611.htm>

LOGO: <http://www.eworldwire.com/newsroom/2611.htm>

CONTACT:

Carlos Garcia
Cytorex Biosciences, Inc
2700 Glades Circle
Suite 138
Weston, FL 33327
PHONE. 954-385-4788
FAX. 954-337-2249
EMAIL: info@cytorex.com
<http://www.cytorex.com>

William Jimenez
Cytorex International, Inc.
Edif Camara de Comercio
Ave. 2 El Milagro Ofic. No. 2
Maracaibo, Venezuela 4001A
PHONE. +58 -414-614-0226
EMAIL: wjimenez@cytorex.com
<http://www.cytorex.com>

KEYWORDS: Cancer, Oncology, Chemotherapy, Cytotoxicity, Toxicity, Medicine, Cytorex.

SOURCE: Cytorex Biosciences, Inc.